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Original ArticleIntestinal CREBH overexpression prevents high-
cholesterol diet-induced hypercholesterolemia
by reducing Npc1l1 expressionTakuya Kikuchi 1, Kana Orihara 1, Fusaka Oikawa 1, Song-iee Han 1, Motoko Kuba 1, Kanako Okuda 1,
Aoi Satoh 1, Yoshinori Osaki 1, Yoshinori Takeuchi 1, Yuichi Aita 1, Takashi Matsuzaka 1, Hitoshi Iwasaki 1,
Shigeru Yatoh 1, Motohiro Sekiya 1, Naoya Yahagi 1, Hiroaki Suzuki 1, Hirohito Sone 2, Yoshimi Nakagawa 1,3,*,
Nobuhiro Yamada 1, Hitoshi Shimano 1,3,4,**ABSTRACT
Objective: The transcription factor cyclic AMP-responsive element-binding protein H (CREBH, encoded by Creb3l3) is highly expressed in the
liver and small intestine. Hepatic CREBH contributes to glucose and triglyceride metabolism by regulating ﬁbroblast growth factor 21 (Fgf21)
expression. However, the intestinal CREBH function remains unknown.
Methods: To investigate the inﬂuence of intestinal CREBH on cholesterol metabolism, we compared plasma, bile, fecal, and tissue cholesterol
levels between wild-type (WT) mice and mice overexpressing active human CREBH mainly in the small intestine (CREBH Tg mice) under different
dietary conditions.
Results: Plasma cholesterol, hepatic lipid, and cholesterol crystal formation in the gallbladder were lower in CREBH Tg mice fed a lithogenic diet
(LD) than in LD-fed WTs, while fecal cholesterol output was higher in the former. These results suggest that intestinal CREBH overexpression
suppresses cholesterol absorption, leading to reduced plasma cholesterol, limited hepatic supply, and greater excretion. The expression of
NiemannePick C1-like 1 (Npc1l1), a rate-limiting transporter mediating intestinal cholesterol absorption, was reduced in the small intestine of
CREBH Tg mice. Adenosine triphosphate-binding cassette transporter A1 (Abca1), Abcg5/8, and scavenger receptor class B, member 1 (Srb1)
expression levels were also reduced in CREBH Tg mice. Promoter assays revealed that CREBH directly regulates Npc1l1 expression. Conversely,
CREBH null mice exhibited higher intestinal Npc1l1 expression, elevated plasma and hepatic cholesterol, and lower fecal output.
Conclusion: Intestinal CREBH regulates dietary cholesterol ﬂow from the small intestine by controlling the expression of multiple intestinal
transporters. We propose that intestinal CREBH could be a therapeutic target for hypercholesterolemia.
 2016 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Cholesterol absorption in the gut has been studied extensively because
of its signiﬁcant positive correlation with plasma cholesterol concen-
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has been demonstrated that the small intestine also excretes large
amounts of endogenous cholesterol [4,5]. Cholesterol uptake from the
lumen by enterocytes is the rate-limiting step in cholesterol absorption
[6], and NPC1L1 plays a pivotal role in this process [7,8]. NPC1L1 is
exclusively expressed in enterocytes of the proximal small intestine [8].
The clinical anti-hypercholesterolemia drug ezetimibe (Zetia) lowers
plasma cholesterol levels by inhibiting NPC1L1 [8,9]. Ezetimibe
treatment in mice increased fecal neutral sterol excretion without
altering hepato-biliary cholesterol disposal into the bile [10]. ATP
binding cassette subfamily G isoforms G5 and G8 are expressed in
both the liver and small intestine where they heterodimerize into a
functional transporter [11] to promote sterol secretion, with a prefer-
ence for plant sterols over cholesterol [12]. In the liver, they are
expressed on the apical membrane of hepatocytes [13] and secrete
both cholesterol and plant sterols into the bile [14,15]. In the small
intestine, they are presumed to be expressed on the apical brush
border membrane of enterocytes and secrete cholesterol and plant
sterols into the intestinal lumen [16].
CREBH is a basic leucine zipper domain transcriptional factor of the
CREB/activating transcription factor family [17]. CrebH is highly and
selectively expressed in gastrointestinal tract tissues, including the
liver, pyloric stomach, duodenum, and ileum [18]. Hepatic CrebH
mRNA expression is regulated by fasting and re-feeding, with nuclear
levels of active CREBH increasing in times of starvation [19]. Translated
CREBH protein localizes to the endoplasmic reticulum (ER) before
transfer to the Golgi apparatus, where the transcriptionally active N-
terminal region is cleaved prior to translocation to the nucleus [19].
CREBH and peroxisome proliferator activated receptor alpha (PPARa)
synergistically activate hepatic ﬁbroblast growth factor 21 (Fgf21)
expression and exert effects on energy metabolism through the
modulation of plasma FGF21 levels [20,21]. CREBH reduces plasma
triglyceride (TG) levels by increasing hepatic gene expression of apo-
lipoproteins such as apolipoprotein A-IV (Apoa4), Apoa5, and Apoc2.
These apolipoproteins activate plasma lipoprotein lipase (LPL),
resulting in reduced plasma TG levels. However, the function of in-
testinal CREBH remains unclear.
To investigate the functions of intestinal CREBH, we generated CREBH
Tg mice and examined effects of CREBH overexpression on cholesterol
metabolism.
2. MATERIALS AND METHODS
2.1. Animals and diets
Wild-type (WT) C57/BL6J mice were obtained from CLEA Japan. To
generate CREBH Tg mice, cDNAs encoding the rat Pck1 promoter,
active human CREBH (amino acids 1e320), and the 30 polyadenylation
signal of human growth hormone were microinjected into C57BL6J
eggs [21]. Creb3l3tm1.1Sad/J (CREBH null) mice [18] were purchased
from The Jackson Laboratory (Bar Harbor, ME, USA). All mice were
housed in a pathogen-free barrier facility under a 12-h light/dark cycle
and given free access to water. Mice were fed a normal chow diet (MF:
Oriental Yeast, Tokyo, Japan) or a lithogenic diet (LD) (16.5% fat,
1.25% cholesterol, 0.5% cholic acid (CA); F2HFD1; Oriental Yeast)
(F2HFD1: Oriental Yeast, Tokyo, Japan) [22] for 2 weeks. All animal
husbandry and experimental protocols conformed to the University of
Tsukuba Regulations of Animal Experiments and were approved by the
Animal Experiment Committee of the University of Tsukuba.
2.2. RNA puriﬁcation and real time-PCR
Total RNA was extracted from frozen mouse tissues using Sepasol
(Nakarai Tesque, Kyoto, Japan). For the analysis of jejunal geneMOLECULAR METABOLISM 5 (2016) 1092e1102  2016 TheAuthor(s). Published by Elsevier GmbH. This is an
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rectum was used. Total RNA was reverse transcribed using the Pri-
meScript RT Master kit (Takara, Bio Inc., Shiga, Japan). Real-time PCR
was performed using the ABI Prism 7300 System with LightCycler-
DNA Master SYBR Green I Mix (Roche Diagnostics Ltd, Lewes, UK).
mRNA expression was normalized to cyclophilin mRNA content and
expressed as fold change compared to control mice using the DDCT
method.
2.3. Immunoblotting
Immunoblotting of whole cell lysates was performed as described
previously [23]. Protein expression levels of NPC1L1 were analyzed in
small intestine lysates using a rabbit anti-NPC1L1 antibody (Novus
Biologicals cat. NB400-127).
2.4. Histological analysis
The liver was ﬁxed, embedded in parafﬁn, sectioned, and stained with
hematoxylin and eosin (H&E).
2.5. Cell culture, transfection, and luciferase assay
Caco-2 cells were maintained in DMEM supplemented with 10%
fetal bovine serum (FBS) and penicillin-streptomycin at 37 C in a
humidiﬁed 5% CO2/95% air environment. Mouse Npc1l1 promoter-
luciferase constructs and expression vectors for CREBH and/or
SREBP-2 were co-transfected into Caco-2 cells using lipofectamine
3000 (Invitrogen, Grand Island, NY, USA). A renilla expression
construct was co-transfected as an internal control for transfection
efﬁciency. At 48 h after transfection, luciferase and renilla activities
were measured using commercial assay systems (Luciferase: Pic-
aGene, Toyo-Inki, Tokyo, Japan; Renilla: Promega, Madison, WI,
USA). The promoter activity was expressed as the ratio of luciferase
to renilla activities in each sample.
2.6. Electrophoretic mobility shift assay
We generated the HA-tagged active form of CREBH from an
expression vector using an in vitro reticulocyte transcriptionetrans-
lation system (Promega). We used the following sequences in the
electrophoretic mobility shift assays (EMSAs): 50-ggaagttgacctca-
gaaggaggagatggaatggca-30 for 106 to 69 of the Npc1l1 pro-
moter; 50-ggcaccatctgatgtaagggaagagaaaataaattattaa-30 for 75
to 33 of the Npc1l1 promoter; 50-gagaaaataaattattaaccagtacgg-30
for 53 to 23 of the Npc1l1 promoter; and 50-gtacggcccagtcc-
tattggccccatgacagacgagg-30 for 32 to þ5 of the Npc1l1 promoter.
We incubated the in vitro-translated protein lysate and anti-HA an-
tibodies (12CA5, Santa Cruz) in a reaction mixture as previously
described [23] and resolved the DNAeprotein complexes on a 4%
polyacrylamide gel.
2.7. Plasma, hepatic, and gallbladder bile lipid and gallstone
analysis
Plasma and liver parameters [23], hepatic bile acids [22], and gall-
bladder bile [22] were analyzed as described previously. Gallbladders
bile was examined for monohydrate cholesterol crystals under polar-
izing light microscopy.
2.8. Fecal cholesterol and bile acids output
Fecal cholesterol and bile acid outputs were measured as described
[24,25]. Brieﬂy, after 2 weeks of normal or LD feeding, mice were
individually housed for fecal collection. The feces were dried, weighed,
and crushed into powder. Fecal bile acids were extracted from
powdered feces with 90% ethanol [24] and concentrations determinedopen access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1093
Original Articleenzymatically using a total bile acids kit (Wako). Fecal cholesterol and
triglycerides were extracted from powdered feces with chloroform/
methanol (2:1 vol/vol) [25] and concentrations determined enzymati-
cally using a total cholesterol kit (Wako).
2.9. Statistical analysis
All results are presented as mean  SEM. Treatment group means
were compared by unpaired sample Student’s t-test and differences
were considered statistically signiﬁcant at p < 0.05.
3. RESULTS
3.1. CREBH Tg mice showed lower plasma cholesterol levels than
WT mice when fed a LD
Endogenous CrebH was broadly expressed in the small intestine,
but expression was higher in jejunum than other subregions
(Supplementary Figure 1A). As the Pck1 promoter is active in the
liver, kidney, brown adipose, and small intestine [26], CREBH Tg
mice overexpressed the active form of human CREBH in small in-
testine, colon, adipose tissues, and muscle (Supplementary
Figure 1A). We conﬁrmed that CREBH Tg mice had 3 copies of
transgene in genome. It was speculated that the position effects of
the transgenic cassette inserted into the genome happened not to
express ectopic CREBH expression in the liver. To conﬁrm the ef-
fects of transgene in the liver, we determined Fgf21 expression,
which is the target of CREBH [20,21], in the liver. There was a trend
to increase Fgf21 expression in CREBH Tg mice, but it was not
signiﬁcant (Supplementary Figure 1A). Thus, there was a low effect
of transgene in the liver of CREBH Tg mice. To explore the effects of
CREBH on cholesterol metabolism, numerous metabolic indices
were ﬁrst compared between WT and CREBH Tg mice fed either a
normal chow diet or a LD for 2 weeks. There were no differences in
body weight, liver weight, white adipose tissue (WAT) weight, or
food intake between WT and CREBH Tg mice fed normal chow or LD
(Figure 1A). There was also no difference in plasma cholesterol
between genotypes when fed a normal chow diet. However, LD-fed
CREBH Tg mice showed 33% lower plasma cholesterol levels
(p < 0.002) compared to LD-fed WT mice (Figure 1B). HPLC
analysis revealed that CREBH Tg mice had lower plasma cholesterol
levels in all lipoprotein fractions, while there were no differences in
plasma triglyceride levels between genotypes (Figure 1B). Plasma
TG, non-esteriﬁed fatty acids (NEFA), and bile acid levels did not
differ between genotypes when fed a LD (Figure 1B). When fed a
normal chow diet, plasma NEFA levels were reduced in CREBH Tg
mice, but other parameters (cholesterol, TG, NEFA, and bile acids)
did not differ (Figure 1B). An LD-induced plasma aspartate
aminotransferase (AST) and alanine aminotransferase (ALT) levels in
CREBH Tg mice has a trend to decrease, but this was not signiﬁcant
(Figure 1B).
3.2. CREBH Tg prevented high cholesterol-diet induced
hypercholesterolemia
WT mice fed with LD for 2 weeks had a white liver, but CREBH Tg
mice did not (Figure 2A). Histological analysis of liver sections
showed that CREBH overexpression decreased lipid droplet accu-
mulation compared to WT mice (Figure 2A). Liver cholesterol and
triglyceride levels were signiﬁcant lower in LD-fed CREBH Tg mice
than LD-fed WT mice (Figure 2B). Liver bile acid levels did not differ
signiﬁcantly between genotypes following a LD (Figure 2B). The
mean gallbladder size of CREBH Tg mice was not different from WTs
(Figure 2C). In this study, we used a LD diet containing 0.5% colic1094 MOLECULAR METABOLISM 5 (2016) 1092e1102  2016 TheAuthor(s). Published by Elsevier GmbHacid, which induces the gallstone formation [27,28]. Gallbladder bile
samples from LD-fed WT and CREBH Tg mice were inspected by light
polarizing microscopy to determine the presence and appearance of
cholesterol monohydrate crystals and sandy stones (Figure 2C).
Average crystal stone size was reduced in CREBH Tg mice compared
to WT mice following the LD (Figure 2D). Cholesterol and bile acids
levels in the gallbladder were also signiﬁcantly lower in CREBH Tg
mice (Figure 2D). CREBH Tg mice had signiﬁcantly lower intestinal
cholesterol levels than WT mice as well (Figure 2E). Conversely,
CREBH Tg mice exhibited signiﬁcantly higher fecal cholesterol output
than WT mice, while fecal bile acid output did not differ between
genotypes (Figure 2E). These results indicate that CREBH over-
expression reduces dietary cholesterol absorption and cholesterol
efﬂux from small intestine, resulting in lower liver and plasma
cholesterol levels and higher fecal excretion.
3.3. CREBH Tg mice fed a LD have reduced intestinal cholesterol
transporter expression
Based on the ﬁnding that CREBH overexpression prevents LD-induced
hypercholesterolemia and cholelithiasis, we performed real time-PCR
to identify possible changes in the intestinal and hepatic expression
levels of lipid metabolism-related genes. Expression levels Npc1l1 and
scavenger receptor class B member 1 (Srb1), genes encoding two
cholesterol transporters that remove cholesterol from the lumen and
into enterocytes, were lower in the small intestine of CREBH Tg mice
than WT mice. In addition, expression levels of Abcg5 and Abcg8,
encoding sterol transporters that excrete cholesterol from enterocytes
into the lumen, were lower in the small intestine of CREBH Tg mice.
Abca1, which plays a crucial role in HDL biosynthesis [29,30], was also
lower in the small intestine of CREBH Tg mice. The expression of liver X
receptor b (Lxrb), a transcriptional regulator of Abcg5 and Abcg8, was
lower in the small intestine of CREBH Tg mice (Figure 3A). Western
blotting analysis conﬁrmed that NPC1L1 protein levels were signiﬁ-
cantly reduced in the small intestine of CREBH Tg mice compared to
WTs following a LD (Figure 3B). These results may partially explain
how intestinal CREBH overexpression increases fecal cholesterol and
decreases plasma cholesterol.
We then compared expression levels of hepatic genes related to
cholesterol synthesis and conversion between WT and CREBH Tg
mice fed a LD. Expression levels of sterol regulatory element-
binding factor (Srebf) family members and their target genes that
regulate hepatic lipid synthesis did not differ between genotypes.
Similarly, hepatic expression levels of the lipid oxidation genes
Ppara and carnitine palmitoyltransferase 1a (Cpt1a) did not differ
between genotypes. In contrast, expression levels of farnesoid X
receptor (Fxr) and small heterodimer partner (Shp), genes regulating
bile acid synthesis, were signiﬁcantly higher in CREBH Tg mice,
resulting in reduced expression of cytochrome P450 family 7 sub-
family a polypeptide 1 (Cyp7a1). These expression changes suggest
reduced hepatic conversion of cholesterol to bile acids in CREBH Tg
mice fed a LD compared to WTs. Therefore, bile acid synthesis was
downregulated in liver of CREBH Tg mice presumably due to
decreased cholesterol inﬂux from the small intestine.
3.4. CREBH reduced Npc1l1 promoter activity
To explain the reduced Npc1l1 expression in CREBH Tg mice, we
examined the effects of CREBH on Npc1l1 promoter activity using a
series of mouse Npc1l1 promoter-luciferase constructs. The mouse
Npc1l1 promoter luc vector and the active form of the CREBH
expression vector were co-transfected into the Caco-2 colon cancer
cell line. CREBH decreased the Npc1l11 promoter activity in a dose-. This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: Overexpression of CREBH in the small intestine reduces plasma cholesterol levels in mice fed a lithogenic diet (LD). Eight-week-old male WT and CREBH Tg
mice were fed a standard chow diet (Chow) or lithogenic diet (LD) for 2 weeks. (A) Body weight, food intake, liver weight, and white adipose tissue (WAT) weight. (B) Plasma
cholesterol (n ¼ 19e31/mice group), triglyceride (n ¼ 10e26/group), NEFA (n ¼ 14e23/group), bile acids (n ¼ 24e38/group), ALT (n ¼ 15e27/group), and AST (n ¼ 15e27/
group). Lipoprotein particle distributions were determined by HPLC analysis. Results presented as mean  SEM. Differences between the genotypes on either nutrient state,
**p < 0.01, *p < 0.05.
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Figure 2: Intestinal CREBH overexpression reduces entero-hepatic system tissue cholesterol in mice fed a LD. (A) The representative pictures of whole livers and liver
sections stained with hematoxylin and eosin (H&E) from LD-fed WT and CREB3 Tg mice. (B) Liver cholesterol, triglyceride, and bile acid levels (n ¼ 8e15 mice/group). (C)
Representative pictures of the gallbladder and images of gallbladder bile analyzed by light polarizing microscopy for the presence of cholesterol monohydrate crystals and sandy
stones. (D) Average gallbladder crystal size in the bile (n ¼ 5/group), and cholesterol and bile acid levels (n ¼ 14e18/group) in gallbladder. (E) Intestinal cholesterol levels (n ¼ 6/
group), intestinal triglyceride levels (n ¼ 6/group), fecal cholesterol output (n ¼ 7e9/group), and fecal bile acid output (n ¼ 4e5/group). Results presented as mean  SEM.
**p < 0.01, *p < 0.05.
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Figure 3: Changes in cholesterol-related gene expression patterns in intestine and liver of WT and CREBH Tg mice fed a LD. Intestinal and hepatic mRNA was extracted
from WT and CREB Tg mice fed a LD for 2 weeks. (A) Expression of cholesterol-related genes in small intestine (n ¼ 6e14 mice/group). (B) Intestinal protein was extracted from
WT and CREBH Tg mice. Western blotting was performed with anti-NPC1L1 antibody. (C) Expression of genes related to lipid and bile acid metabolism in liver (n ¼ 6e7/group).
Results presented as mean  SEM. ***p < 0.001, **p < 0.01, *p < 0.05.dependent manner using the 0.3 kbp mouse Npc1l1 promoter luc
vector (Figure 4A). A previous study reported that SREBP-2 increased
Npc1l1 promoter activity [31], and CREBH signiﬁcantly suppressed
SREBP-2-induced Npc1l1 promoter activity (Figure 4B). SREBP-2 did
not induce 92 bp luc vector, suggesting that the binding site of
SREBP-2 might lie in the region from 300 to 92 bp of the Npc1l1
promoter. CREBH expression decreased the luciferase activity of
the 93 bp mouse Npc1l1 promoter but did not change the activity of
the control luc vector, suggesting that the promoter region responsible
for CREBH regulation lies 93 bp to the transcription start site
(Figure 4B). To conﬁrm the binding site of CREBH in the mouse Npc1l1
promoter, we performed the EMSA assay. In vitro translated CREBH
proteins bound to32 andþ5 bp of Npc1l1 promoter, but not to otherMOLECULAR METABOLISM 5 (2016) 1092e1102  2016 TheAuthor(s). Published by Elsevier GmbH. This is an
www.molecularmetabolism.comregions (Figure 4C). Taken together, these results indicate that CREBH
directly regulates Npc1l1 expression.
3.5. CREBH null mice showed severe hypercholesterolemia
If the phenotypes observed in Tg mice are indeed due to intestinal
CREBH overexpression, CREBH deﬁciency would be expected to
have opposite effects on cholesterol absorption, accumulation,
excretion, and transporter expression. Indeed, CREBH null mice
showed signiﬁcantly higher plasma cholesterol levels than WT
mice (Figure 5A). Plasma TG levels were also higher in CREBH null
mice, but the difference was not signiﬁcant. There were no dif-
ferences in plasma NEFA levels between WT and null mice. In
contrast to CREBH Tg mice, the livers of CREBH null mice showedopen access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1097
Figure 4: CREB3L3 reduces Npc1l1 promoter activity. Caco-2 cells were co-transfected with a luciferase reporter plasmid containing segments of the mouse Npc1l1 promoter
and a CREBH or empty expression plasmid. Forty-eight hours after transfection, the cells were harvested and luciferase assay was performed. (A) CREBH inactivated the 0.3 kbp
Npc1l1 promoter luc in a dose-dependent manner. (B) The effects of CREBH and SREBP-2 on a series of Npc1l1 promoter luc vectors. (C) EMSA assay indicated that CREBH directly
bound to the region from 32 to þ5 bp of the Npc1l1 promoter. n ¼ 3e4/group. ***p < 0.001, **p < 0.01, and *p < 0.05.
Original Articlemassive lipid accumulation (Figure 5B) as revealed by H&E staining
(Figure 5B). Also contrary to the phenotype of LD-fed CREBH Tg
mice, CREBH null mice exhibited higher liver and intestinal
cholesterol levels compared to WT mice (Figure 5C and D). CREBH
null exhibited lower fecal cholesterol output than WTs (Figure 5E).
Intestinal Npc1l1 expression by CREBH null mice was signiﬁcantly
higher than that by WT mice under the normal chow diet. Even if
feeding a LD suppressed Npc1l1 expression, CREBH null mice had
a tendency to increase its expression, but not signiﬁcantly
(Figure 5F). These ﬁndings indicate that CREBH deﬁciency in-
creases cholesterol absorption in small intestine, possibly by
allowing Npc1l1 upregulation, thereby elevating plasma, liver, and
intestinal cholesterol.
4. DISCUSSION
CREBH is highly expressed in liver and small intestine, suggesting
that CREBH regulates both nutrient absorption and metabolism.
CREBH null mice exhibited increased plasma triglyceride and NEFA
levels but decreased plasma cholesterol when fasting [32] and on
an atherogenic high-fat diet [33]. CREBH enhanced LPL activity by
upregulating the expression of hepatic apolipoprotein genes Apoa4,
Apoc2, and Apoa5, thereby increasing triglyceride clearance [32]. In1098 MOLECULAR METABOLISM 5 (2016) 1092e1102  2016 TheAuthor(s). Published by Elsevier GmbHaddition, CREBH upregulated hepatic fatty acid oxidation by
increasing Ppara and its target genes [21]. These effects explain the
plasma TG-lowering effects of liver CREBH. Recently, we generated
liver-speciﬁc CREBH knockout (CREBH L-KO) mice using the
CRISPR/Cas9 system [34] and found higher plasma cholesterol,
triglyceride, and NEFA levels. Expression of hepatic cholesterol
synthesis genes such as Hmgcs1 and Hmgcr were also increased in
the liver of CREBH L-KO mice, consistent with the higher plasma
cholesterol levels [34]. Conversely, mice infected with an adenovirus
encoding the active form of CREBH showed reduced plasma
cholesterol associated with downregulated hepatic expression of
Hmgcs1 and Hmgcr [21]. Taken together, these ﬁndings indicate
that CREBH has a crucial role in hepatic cholesterol synthesis.
However, the functions of CREBH in small intestine and enter-
ohepatic circulation remained unclear.
In the current study, we show that CREBH Tg mice have lower plasma
cholesterol levels than WT mice when fed a LD, suggesting that in-
testinal CREBH contributes to cholesterol metabolism in small in-
testine under cholesterol and cholic acid loading. LD-fed CREBH Tg
mice also exhibited reduced liver cholesterol, liver injury, intestinal
cholesterol, and bile acid levels in gallbladder, and increased fecal
cholesterol. These changes suggest that CREBH Tg mice have lower
intestinal cholesterol absorption. Indeed, gene expression analysis. This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 5: CREBH knockout induces severe hypercholesterolemia in mice fed a LD. (A) Plasma cholesterol (n ¼ 6e11/group), triglyceride (n ¼ 10/group), and NEFA levels
(n ¼ 10/group) in WT and CREBH null mice fed a LD for 2 weeks. (B) Representative pictures of whole livers and. H&E stained liver sections from LD-fed WT and CREBH null mice.
(C) Liver cholesterol and triglyceride levels (n ¼ 6e10/group). (D) Intestinal cholesterol and triglyceride levels (n ¼ 3e5/group). (E) Fecal cholesterol output (n ¼ 4e5/group). (F)
Expression of Npc1l1 in small intestine following normal chow diet or LD. Results presented as mean  SEM. *p < 0.05.revealed downregulation of cholesterol transporters Npc1l1, Srb1,
Abca1, and Abcg5/8 in the small intestine of CREBH Tg mice. NPC1L1
is a rate-limiting transporter of cholesterol absorption in small in-
testine and a key modulator of systemic cholesterol homeostasis
[8,16]. Ezetimibe, an anti-hypercholesterolemia drug, is an inhibitor
of NPC1L1 [35]. Npc1l1 is expressed in the liver and small intestine inMOLECULAR METABOLISM 5 (2016) 1092e1102  2016 TheAuthor(s). Published by Elsevier GmbH. This is an
www.molecularmetabolism.comhuman but is expressed only in the small intestine in mice [8]. Thus,
the effect of Ezetimibe administration mainly depends on the small
intestine. Ezetimibe induces a complete resistance to cholesterol
gallstone formation [36] and nonalcoholic fatty liver disease in
addition to its effect on hypercholesterolemia in mice on a Western
diet [37]. Ezetimibe inhibits the development of fatty liver in mice fedopen access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1099
Figure 6: The scheme of cholesterol ﬂow in CREBH Tg mice.
Original Articlea high-fat diet by inhibiting SREBP-1 activation [38]. As LD-fed
NPC1L1 KO mice showed lower plasma and liver cholesterol levels
[16,39], the reduction of NPC1L1 in the small intestine of CREBH Tg
mice likely contributes to the low plasma cholesterol phenotype and
the suppression of fatty liver development. An Npc1l1 deﬁciency in
small intestine led to reduced intestinal expression of Abca1 and
Abcg5/8 [7,37], genes encoding sterol transporters. Net cholesterol
uptake into enterocytes of the small intestine depends on the balance
between NPC1L1-mediated uptake [8] and ABCG5/8-mediated
excretion [40]. CREBH Tg mice showed a reduction in intestinal
cholesterol levels and an increase in fecal cholesterol, suggesting
that the predominant effect of CREBH overexpression is reduced
NPC1L1-mediated uptake (Figure 6). Intestinal ABCA1 deﬁciency
leads to deﬁcient HDL biogenesis, thereby reducing cholesterol inﬂux
into the circulation [29,30]. SRB1 is involved in the production of
intestinal chylomicrons [41], which mediate the uptake of cholesterol
from the lumen of the proximal small intestine [42,43]. Reduced
expression of these genes in small intestine of CREBH Tg mice likely
also contributes to the reduced absorption and elevated excretion of
cholesterol. As Abca1, Abcg5/8, and Srb1 are regulated by LXRb in
the small intestine [44e47], the decrease of Lxrb expression may
contribute to the reduced these expression in LD-fed CREBH Tg mice.
Excessive amounts of cholesterol are lipogenic through activation of
LXR by its metabolites [48]. The decrease of intestinal cholesterol
levels in CREBH Tg mice also reduces endogenous ligands of LXR and
subsequent LXR activation. Intestinal Npc1l1 expression is upregu-
lated by SREBP-2 and downregulated by PPARa [31,49]. Promoter
analysis revealed that CREBH dose-dependently suppressed Npc1l1
promoter activity and SREBP-2-induced Npc1l1 expression. We
identiﬁed the direct binding sites for CREBH in 32 to þ5 bp of the
Npc1l1 promoter. Both CREBH and SREBP-2 are membrane bound
transcription factors that respond to changes in cellular energy
charge. In liver, CREBH functions in opposition to SREBP family
members in the regulation of triglyceride and cholesterol homeo-
stasis. As CREBH directly binds to SREBP-1 and suppresses SREBP-1
transcriptional activity (Nakagawa, unpublished data), there is a
possibility that CREBH also binds to SREBP-2. SREBP-2 upregulates1100 MOLECULAR METABOLISM 5 (2016) 1092e1102  2016 TheAuthor(s). Published by Elsevier GmbHNpc1l1 expression in response to cholesterol depletion [31]. Simi-
larly, intestinal CREBH and SREBP-2 may act reciprocally to ensure
balanced systemic cholesterol levels through regulation of
absorption.
Systemic cholesterol levels depend on the balance among intestinal
absorption, hepatic synthesis, and hepatic conversion into bile acids. In
light of the low cholesterol phenotype conferred by intestinal CREBH
overexpression, we suggest that CREBH contributes to systemic
cholesterol homeostasis by regulating cholesterol absorption in small
intestine as well as by modulating hepatic synthesis and conversion. In
the liver of CREBH Tg mice, the conversion of cholesterol into bile acids
was likely downregulated as a secondary consequence of reduced liver
cholesterol input. As we are generating small intestine-speciﬁc CREBH
KO mice now, we will reveal the function of CREBH in the small in-
testine in detail.
This study and our unpublished data indicate that intestinal CREBH
regulates TG and cholesterol absorption. Hepatic CREBH regulates TG
and cholesterol catabolism [10,33,34]. Taken together, we propose
that CREBH governs systemic lipid metabolism via entero-hepatic
circulation.
In summary, this study suggests that intestinal CREBH functions as a
metabolic regulator to attenuate diet-induced hypercholesterolemia
and cholelithiasis by decreasing expression of the transporter gene
Npc1l1. It is known that hepatic CREBH has the potential to ameliorate
hypertriglyceridemia. This study identiﬁes intestinal CREBH as another
possible therapeutic target for the treatment of hypercholesterolemia
and related metabolic diseases. Thus, drugs controlling CREBH activity
throughout the intestinalehepatic system could be highly efﬁcacious
treatments for metabolic diseases.
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